Tesla gains as Musk buys $1 billion in stock; closes well-off highs
Investing.com -- Elanco Animal Health (NYSE:ELAN) stock rose 2.6% following the European Commission’s approval of Zenrelia, a once-daily oral treatment for canine allergic dermatitis.
The approval represents a significant expansion of Elanco’s pet health portfolio in Europe, with the company describing Zenrelia as its "most rapidly expanding product." The medication, which contains the active ingredient ilunocitinib, is designed to control itching associated with allergic dermatitis and treat atopic dermatitis in dogs at least 12 months of age.
Elanco conducted a head-to-head non-inferiority study against Apoquel, the current market leader, as part of the EU approval process. The randomized, double-blind study involving 338 dogs across 25 sites in four countries demonstrated that one daily dose of Zenrelia is at least as effective as the competing JAK inhibitor at the primary endpoint on Day 28.
"We’re excited to bring Zenrelia to veterinarians and pet owners in Europe and provide a new solution to bring relief to itchy dogs, while changing the standard of care to a single daily dose," said Ramiro Cabral, Executive Vice President of Elanco International. The company indicated that product launch will begin immediately, with supply availability expected in the third quarter.
Zenrelia is already available in Brazil, Canada, Japan, and the United States, with Elanco anticipating additional approvals in key markets. The EU approval maintains a consistent label with other markets outside North America where the product has already been approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.